Product Pillars - OPS Peptide Science

Peptide Education, Product Pillars, Research Protocols

MOTS-c: Complete Research Guide to the Mitochondrial-Derived Peptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: MOTS-c is a research peptide intended for in-vitro and animal research applications only. It is not FDA-approved as a drug or therapy. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide that has become a focal compound in modern metabolic and longevity research. Unlike most synthetic research peptides, MOTS-c is encoded by mitochondrial DNA rather than nuclear DNA — making it one of a small group of “mitochondrial-derived peptides” (MDPs) discovered relatively recently. Research has documented MOTS-c influencing insulin sensitivity, mitochondrial biogenesis, exercise-mimetic effects, and metabolic biomarker panels in animal models. This complete guide from the chemistry team at OPS Peptide Science walks through what MOTS-c is, how the mitochondrial-origin mechanism works, and where it sits in the broader research catalog.

For the foundational research-workflow protocols, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is MOTS-c?

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c) is a 16-amino-acid peptide encoded within the human mitochondrial 12S rRNA gene. The mitochondrial origin is biologically unusual — most peptides studied in research are encoded by nuclear DNA, while MOTS-c emerges from the small genome that mitochondria carry as a relic of their evolutionary origin as separate organisms.

Key facts about MOTS-c:

Chemical class — 16-amino-acid mitochondrial-derived peptide (MDP)
Molecular weight — approximately 2174 Da
Source — encoded by mitochondrial DNA (12S rRNA region), not nuclear DNA
Sequence — Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (MRWQEMGYIFYPRKLR)
Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
Half-life — relatively short; research models use frequent dosing
Stability — stable at -20°C as lyophilized powder for 18-24 months

The mitochondrial origin makes MOTS-c part of a small but growing class of research compounds — mitochondrial-derived peptides (MDPs). Other MDPs include humanin and the SHLP (small humanin-like peptide) family. MOTS-c is the most-studied of this group due to its metabolic effects.

MOTS-c Structure and Chemistry

MOTS-c’s structure is unusual for a peptide research compound:

16 amino acids — small enough for synthetic production at high purity
Encoded by mitochondrial 12S rRNA — an unusual coding location for a functional peptide
Naturally produced — research has documented endogenous MOTS-c in human and animal tissues, particularly in muscle
Levels respond to exercise — published research has measured MOTS-c rising with exercise, supporting the “exercise-mimetic” research framing
Levels decline with age — like many bioactive peptides, MOTS-c concentrations decrease in older subjects

The age-related decline and exercise-induced increase are what make MOTS-c interesting as a research target — both findings suggest MOTS-c is part of the cellular machinery that responds to metabolic stress and aging. Studying exogenous MOTS-c administration probes whether supplementing the natural decline produces measurable effects on the same pathways.

How MOTS-c Works in Research (Mechanism)

The MOTS-c mechanism is one of the better-characterized in modern research peptide science. Documented pathways include:

AMPK activation — MOTS-c activates AMP-activated protein kinase, a central cellular energy sensor that regulates metabolism
Folate-methionine cycle modulation — research has documented effects on one-carbon metabolism, which sits upstream of multiple cellular pathways
Mitochondrial biogenesis — induces new mitochondrial formation in research models, increasing cellular mitochondrial density
Glucose homeostasis — improves insulin sensitivity and glucose disposal in animal research models
Skeletal muscle metabolism — particularly active in muscle tissue, where MOTS-c affects glucose uptake and fatty acid oxidation
Mitochondrial-nuclear signaling — MOTS-c travels from mitochondria to nucleus, where it influences gene expression

The AMPK activation mechanism positions MOTS-c alongside compounds like metformin in mechanistic research — both activate AMPK, though through different upstream signals. The mitochondrial-nuclear signaling component is particularly novel for research peptides — MOTS-c demonstrates that mitochondria don’t just produce energy; they also send signaling molecules that influence nuclear gene expression. The published MOTS-c research literature on PubMed documents these mechanisms across the past decade of investigation.

MOTS-c Research Applications

Metabolic Research

The largest body of MOTS-c research focuses on metabolic endpoints — insulin sensitivity, glucose tolerance, lipid profiles, and broader metabolic biomarker panels. Animal models studying type 2 diabetes biology, metabolic syndrome research, and obesity-related metabolic disorders have produced consistent MOTS-c data across multiple studies.

Exercise-Mimetic Research

Because endogenous MOTS-c rises with exercise, the compound has been studied as a potential “exercise mimetic” — producing some of exercise’s metabolic effects without physical activity. Research models have documented MOTS-c effects on muscle glucose uptake, mitochondrial biogenesis, and aerobic capacity markers that overlap with exercise adaptations.

Mitochondrial Biology Research

MOTS-c is one of the central research compounds in mitochondrial biology — investigating mitochondrial-nuclear communication, mitochondrial biogenesis pathways, and mitochondrial dysfunction in aging and disease models. The compound’s mitochondrial origin makes it uniquely positioned as a research probe for mitochondrial signaling.

Aging and Longevity Research

The age-related decline in endogenous MOTS-c has driven longevity research applications. Studies have measured effects on aging-related biomarkers, healthspan endpoints, and mitochondrial function across age cohorts in animal models. MOTS-c sits alongside SS-31, NAD+ precursors, and other mitochondrial compounds in the longevity research portfolio.

Bone Research

Emerging research area — MOTS-c has been documented in bone biology research models, with effects on osteoblast activity and bone density markers. This area is smaller than the metabolic research but growing.

MOTS-c Dosing in Research Models

Research dosing patterns for MOTS-c in published studies:

Subcutaneous or intraperitoneal injection — both routes appear in published animal research
Daily dosing common — short half-life supports daily administration in most protocols
Cycle-based protocols — some research designs use 4-12 week dosing cycles with washout periods
Dose amounts — typically reported in mg/kg body weight in animal research; specific protocols vary by species and endpoint
Endpoint timelines — metabolic endpoints typically measured at 4-8 weeks; longevity endpoints over longer durations

Research protocols should reference published methodology for the specific research model. The acute vs. cumulative effect timeline distinction is addressed in our guide on how long does it take for peptides to work.

MOTS-c Storage and Stability

MOTS-c stability is comparable to other small lyophilized research peptides:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our guide on how long do peptides last at room temperature.

MOTS-c vs SS-31 and Other Mitochondrial Compounds

Several research compounds target mitochondrial biology. Brief comparison:

Compound	Type	Mechanism	Primary Research Focus
MOTS-c	Mitochondrial-derived peptide	AMPK activation, gene expression	Metabolism, insulin sensitivity, exercise mimicry
SS-31 (elamipretide)	Synthetic peptide	Cardiolipin binding, membrane stabilization	Cardiac, neurodegeneration, mitochondrial membrane
Humanin	Mitochondrial-derived peptide	Anti-apoptotic, cytoprotective	Neurodegeneration, cell survival
NAD+ precursors	Small molecule	NAD+ pool expansion	Sirtuin activation, aging biology

MOTS-c and SS-31 are the two most-cited mitochondrial peptides in modern research. They address different aspects of mitochondrial biology — MOTS-c affects gene expression and metabolic signaling, SS-31 stabilizes the inner mitochondrial membrane. Many research designs use them in parallel rather than as alternatives.

How to Identify Quality Research-Grade MOTS-c

Quality criteria for research-grade MOTS-c:

99%+ HPLC-MS verified purity — small peptide synthesis is generally manageable, but verification is essential for reproducible research
Per-lot Certificate of Analysis — each batch independently tested
Mass spectrometry identity confirmation — confirms molecular weight matches MOTS-c (~2174 Da)
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every MOTS-c vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity and identity before opening the vial.

MOTS-c Regulatory Status

MOTS-c sits in standard research-peptide regulatory territory:

Not FDA-approved — has not completed clinical trials required for human drug approval
Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
Not WADA-prohibited — as of current updates, MOTS-c is not on the WADA Prohibited List, though this could change with future updates
Not DEA-scheduled — no controlled substance status
Newer compound — discovered around 2015, so regulatory frameworks are still adapting

For the complete legal framework around research peptides, see our detailed guide on are peptides illegal. According to NIH research literature, MOTS-c remains an active area of pre-clinical investigation, particularly in metabolic and longevity contexts.

FAQ

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA (specifically the 12S rRNA gene). It is one of a small class of “mitochondrial-derived peptides” (MDPs). Research has documented effects on insulin sensitivity, mitochondrial biogenesis, AMPK activation, and metabolic biomarker panels across animal research models.

What makes MOTS-c different from other peptides?

Two things. First, MOTS-c is encoded by mitochondrial DNA rather than nuclear DNA — unusual for a peptide. Second, MOTS-c demonstrates mitochondrial-nuclear signaling, where mitochondria send a peptide that influences nuclear gene expression. These features make MOTS-c a unique research probe for mitochondrial biology.

How does MOTS-c work?

MOTS-c activates AMP-activated protein kinase (AMPK), a central cellular energy sensor. AMPK activation produces downstream effects on glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and metabolic gene expression. MOTS-c also modulates folate-methionine cycle activity and travels from mitochondria to nucleus to influence gene expression directly.

Is MOTS-c an exercise mimetic?

Some research uses this framing because endogenous MOTS-c levels rise with exercise. Animal research has documented overlap between MOTS-c administration and exercise-induced adaptations — muscle glucose uptake, mitochondrial biogenesis, aerobic capacity markers. This doesn’t mean MOTS-c replaces exercise; it suggests both engage similar metabolic pathways.

What’s the difference between MOTS-c and SS-31?

Both target mitochondria but through different mechanisms. MOTS-c is mitochondrial-encoded and acts through AMPK and gene expression. SS-31 is a synthetic peptide that binds cardiolipin in the mitochondrial membrane, providing structural stabilization. Research often uses them as complementary tools — MOTS-c for signaling/metabolic endpoints, SS-31 for membrane and bioenergetics endpoints.

Is MOTS-c legal in the US?

Yes — MOTS-c is legally sold in the US as a research chemical for in-vitro and animal research under research-use-only labeling. It is not FDA-approved and is not currently on the WADA Prohibited List. See our detailed guide on are peptides illegal for the full framework.

Where can I buy research-grade MOTS-c?

Research-grade MOTS-c is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and traceable chain-of-custody. Browse the OPS Peptide Science catalog for verified research-grade MOTS-c.

MOTS-c represents a new class of research peptides — mitochondrial-derived peptides that demonstrate mitochondria-nuclear signaling. The AMPK activation mechanism, exercise-mimetic profile, and metabolic effects make MOTS-c one of the most cited compounds in modern metabolic and longevity research. For researchers studying mitochondrial biology, insulin sensitivity, or aging endpoints, MOTS-c is among the most-referenced peptides in the modern research catalog.

For research-grade MOTS-c backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Product Pillars, Peptide Education, Research Protocols

CJC-1295 + Ipamorelin: Complete Research Guide to the GH Secretagogue Stack

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: CJC-1295 and Ipamorelin are research peptides intended for in-vitro and animal research applications only. They are not FDA-approved as drugs or therapies. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

CJC-1295 and Ipamorelin together form the most-studied growth hormone secretagogue stack in modern peptide research. Each compound acts on a distinct receptor — CJC-1295 mimics growth hormone-releasing hormone (GHRH), while Ipamorelin mimics ghrelin at the GHS-R receptor — producing synergistic growth hormone release that exceeds what either compound delivers alone. This complete guide from the chemistry team at OPS Peptide Science walks through how each compound works, why researchers combine them, the DAC vs. no-DAC distinction for CJC-1295, and how the stack sits in the broader peptide research catalog.

For the foundational research-workflow protocols this guide assumes, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Are CJC-1295 and Ipamorelin?

CJC-1295 and Ipamorelin belong to two distinct classes of growth hormone secretagogues:

CJC-1295 — a GHRH (growth hormone-releasing hormone) analog; mimics the body’s natural signal to the pituitary to release growth hormone
Ipamorelin — a GHRP (growth hormone-releasing peptide); mimics ghrelin at the GHS-R receptor and triggers growth hormone release through a separate pathway

Each compound activates a different receptor on the same target cells — pituitary somatotrophs. Combining the two simultaneously activates both pathways, producing more growth hormone release than either alone. This complementary mechanism is what makes the CJC-1295 + Ipamorelin combination the most-cited GH secretagogue stack in research literature.

CJC-1295 Structure and Mechanism

CJC-1295 is a synthetic analog of GHRH (growth hormone-releasing hormone). Key features:

30-amino-acid peptide — based on the first 29 amino acids of natural GHRH, with a 30th residue modification
Position 2 substitution — replaces alanine with D-alanine, preventing DPP-4 enzymatic degradation
Two forms exist — with DAC (long-acting) and without DAC (short-acting, also called Mod GRF 1-29)
Binds GHRH receptors on pituitary somatotrophs — same receptor as natural GHRH

The DAC (Drug Affinity Complex) modification is what differentiates the two CJC-1295 forms. With DAC, the peptide includes a maleimidopropionic acid linker that binds covalently to circulating serum albumin, extending the half-life from minutes to 6-8 days. Without DAC, CJC-1295 (Mod GRF 1-29) has a half-life of approximately 30 minutes — supporting pulsatile dosing protocols that mimic natural GHRH release patterns.

Ipamorelin Structure and Mechanism

Ipamorelin is a synthetic pentapeptide (5 amino acids) belonging to the growth hormone-releasing peptide (GHRP) class. Key features:

Pentapeptide — Aib-His-D-2-Nal-D-Phe-Lys-NH2 (5 amino acids with modifications for stability)
Molecular weight — approximately 712 Da
Half-life — approximately 2 hours
Binds the ghrelin receptor (GHS-R) — the same receptor activated by natural ghrelin
Highly selective — minimal effect on cortisol and prolactin compared to older GHRPs (GHRP-2, GHRP-6, hexarelin)

The selectivity of Ipamorelin is what made it stand out among GHRPs in research. Older GHRPs produce GH release but also raise cortisol and prolactin to varying degrees — which complicates research data interpretation. Ipamorelin produces measurable GH release with minimal off-target effects, making it the preferred GHRP for clean research designs.

Why Combine CJC-1295 and Ipamorelin?

Combining a GHRH analog (CJC-1295) with a GHRP (Ipamorelin) produces a synergistic effect that exceeds either compound alone. The mechanism explains why:

Two receptors, one target cell — CJC binds GHRH receptors while Ipamorelin binds GHS-R receptors, both on the same pituitary somatotrophs
Different intracellular signaling pathways — GHRH-R activates cAMP signaling; GHS-R activates phospholipase C/Ca²⁺ signaling
Convergent on GH release — both pathways end in growth hormone release, but they prime the cell through different signals
Documented synergy in research — combined administration produces 5-7x more GH release than either alone in published animal research models

The combination also restores more of the natural pulsatile GH release pattern than either compound alone — the GHRH signal “primes” the cell while the GHRP signal “triggers” release, mirroring how natural GHRH and ghrelin work together physiologically. The published CJC-1295 and Ipamorelin research literature on PubMed documents this synergy across multiple research models.

CJC-1295 + Ipamorelin Research Applications

Growth Hormone Research

The largest body of CJC-1295 + Ipamorelin research focuses on growth hormone secretion itself — measuring acute GH pulses, peak heights, and cumulative GH exposure over dosing periods. This research provides the foundation for understanding the stack’s downstream effects.

IGF-1 Trajectory Research

Growth hormone stimulates IGF-1 production primarily in the liver. Research using CJC-1295 + Ipamorelin protocols measures IGF-1 trajectories over weeks of dosing — capturing how repeated GH stimulation builds steady-state IGF-1 elevation. This is a key endpoint for studies examining downstream metabolic and tissue effects.

Body Composition Research

Animal research models studying body composition — lean mass, fat mass, distribution — use CJC-1295 + Ipamorelin protocols because elevated IGF-1 produces measurable body composition shifts over 6-12 weeks of consistent dosing.

Sleep Research

Growth hormone is closely linked to slow-wave sleep, and research on GH-stimulating peptides extends into sleep biology endpoints. CJC-1295 + Ipamorelin research has documented effects on sleep architecture in animal models.

Bone Density Research

GH and IGF-1 are central to bone metabolism. Research models studying bone density, bone turnover markers, and broader skeletal biology have documented CJC-1295 + Ipamorelin effects across multi-month protocols.

Tissue Repair Research

GH and IGF-1 support cellular repair processes. Some research models pair CJC-1295 + Ipamorelin with tissue-injury models to study repair endpoints — though specific tissue-repair compounds like BPC-157 and TB-500 remain more cited for direct repair research.

CJC-1295 With DAC vs Without DAC

The DAC distinction is one of the most important decisions in CJC-1295 research protocol design:

Property	CJC-1295 with DAC	CJC-1295 No DAC (Mod GRF 1-29)
Half-life	~6-8 days	~30 minutes
Dosing frequency	Weekly	Multiple times daily
GH release pattern	Continuous elevated	Pulsatile (mimics natural)
Receptor occupancy	Sustained	Episodic
Research use	Long-term effect studies	Pulsatile pattern research

Research design considerations:

For cumulative IGF-1 trajectory research — CJC-1295 with DAC is more practical due to weekly dosing
For pulsatile GH biology research — Mod GRF 1-29 (no DAC) more closely matches natural GHRH pulse patterns
Most combination research — uses no-DAC CJC-1295 paired with Ipamorelin in multiple-daily protocols to mimic natural GH release
Long-term metabolic studies — sometimes use DAC version for simpler weekly protocols

The choice depends on what research endpoint you’re studying. Neither form is universally “better” — they serve different research questions.

Dosing in Research Models

Combination CJC-1295 + Ipamorelin dosing patterns in published research:

Subcutaneous injection — standard route for both compounds in research models
Pre-sleep administration — common in research protocols to align with natural GH release peaks during slow-wave sleep
Multiple daily dosing — when using no-DAC CJC-1295, 2-3 doses per day to mimic pulsatile patterns
Single weekly dose — when using DAC CJC-1295, simpler protocol logistics
Cycle protocols — many research designs use 8-12 week dosing cycles with washout periods to study sustained effects
Dose amounts — typically reported in μg/kg in animal research; specific protocols vary by species and endpoint

Storage and Stability

Both compounds follow standard peptide stability profiles:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For research designs combining both peptides, OPS Peptide Science offers a pre-mixed CJC-1295 + Ipamorelin blend that simplifies the workflow — both compounds reconstituted together at standardized ratios. For protocols requiring independent dose control, separate vials of each compound are also available. See our companion guide on how long do peptides last at room temperature for detailed stability information.

How to Identify Quality CJC-1295 + Ipamorelin

Both compounds are technically demanding to synthesize cleanly. Quality criteria:

99%+ HPLC-MS verified purity for both compounds independently if sold separately, or for the blend if pre-mixed
Per-lot Certificate of Analysis documenting each compound’s purity and identity
Mass spectrometry identity confirmation — CJC-1295 (~3367 Da with DAC, ~3367 Da without DAC for Mod GRF 1-29 differs slightly), Ipamorelin (~712 Da)
Clear DAC vs no-DAC labeling — these are distinct products; mislabeling is a quality red flag
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every CJC-1295 and Ipamorelin vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity, identity, and DAC status (where applicable) before opening the vial.

Regulatory Status

CJC-1295 and Ipamorelin occupy similar regulatory positions:

Not FDA-approved — neither compound has completed clinical trials required for US drug approval
WADA-prohibited in athletic competition (peptide hormones / growth factors category)
Legal as research chemicals — sold in the US for in-vitro and animal research under research-use-only labeling
Not DEA-scheduled — no controlled substance status
Removed from compounding lists — recent FDA actions have restricted pharmacy compounding access for these compounds

For the complete legal framework around research peptides like CJC-1295 and Ipamorelin, see our detailed guide on are peptides illegal. According to NIH research literature, both compounds remain active pre-clinical research areas despite the regulatory restrictions on human use.

FAQ

What is CJC-1295?

CJC-1295 is a 30-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotrophs and stimulates growth hormone release. Two forms exist: with DAC (6-8 day half-life) and without DAC, also called Mod GRF 1-29 (~30 minute half-life).

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide that mimics ghrelin at the GHS-R receptor, triggering growth hormone release. It is highly selective for GH release with minimal effects on cortisol and prolactin, distinguishing it from older GHRPs (GHRP-2, GHRP-6, hexarelin).

Why combine CJC-1295 and Ipamorelin?

The two compounds activate different receptors (GHRH-R and GHS-R) on the same pituitary cells. Combined administration produces synergistic growth hormone release — published research documents 5-7x more GH release than either alone in animal models. The combination also better mimics natural pulsatile GH biology.

Should I use CJC-1295 with DAC or without DAC?

Depends on the research design. With DAC supports weekly dosing for long-term IGF-1 trajectory and metabolic research. Without DAC (Mod GRF 1-29) supports multiple-daily dosing for pulsatile GH biology research. Most combination research uses no-DAC paired with Ipamorelin to mimic natural pulsatile release patterns.

Is CJC-1295 + Ipamorelin legal in the US?

Yes — both compounds are legally sold as research chemicals for in-vitro and animal research under research-use-only labeling. Neither is FDA-approved for human use, and WADA prohibits both in athletic competition. See our detailed guide on are peptides illegal for the full framework.

How long does it take to see effects from CJC-1295 + Ipamorelin in research?

Acute GH release peaks within 30-90 minutes of administration in research models. Cumulative IGF-1 elevation builds over 2-4 weeks of consistent dosing. Body composition and metabolic endpoints typically require 6-12 weeks. Specific timelines depend on the research endpoint being measured.

Where can I buy research-grade CJC-1295 + Ipamorelin?

Research-grade CJC-1295 and Ipamorelin are sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity for each compound, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and clear DAC vs no-DAC labeling. Browse the OPS Peptide Science catalog for verified research-grade CJC-1295 and Ipamorelin, including pre-mixed blends.

The CJC-1295 + Ipamorelin combination remains the gold-standard growth hormone secretagogue stack in modern peptide research. The dual-receptor mechanism produces synergistic GH release that exceeds either compound alone, supporting research across growth hormone biology, IGF-1 trajectories, body composition, sleep biology, and bone density endpoints. For researchers studying the GH axis at any level, this stack is one of the most-cited combinations in the modern catalog.

For research-grade CJC-1295 and Ipamorelin backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Uncategorized, Peptide Education, Product Pillars, Research Protocols

GHK-Cu: Complete Research Guide to the Copper Tripeptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: GHK-Cu is a research peptide intended for in-vitro and animal research applications. Cosmetic-grade GHK-Cu formulations exist as permitted cosmetic ingredients and are distinct from research-grade compound. Nothing in this article constitutes medical advice, dermatologic guidance, or instructions for personal use.

GHK-Cu — glycyl-L-histidyl-L-lysine bound to a copper ion — is one of the most extensively studied copper peptides in dermal biology research. The compound occurs naturally in human plasma at concentrations that decline progressively with age, a feature that has driven decades of research interest. Published literature documents GHK-Cu modulating over 4,000 genes related to repair, regeneration, and aging biology — making it one of the most mechanistically diverse research peptides in the modern catalog. This complete guide from the chemistry team at OPS Peptide Science walks through what GHK-Cu is, how it works, and where it sits across skin biology, wound healing, and gene expression research.

For the broader skin biology research context, see our companion guides on what do copper peptides do for your skin, can you use peptides with retinol, and peptides for anti-aging and longevity.

What Is GHK-Cu?

GHK-Cu is a copper-binding tripeptide consisting of three amino acids — glycine, L-histidine, and L-lysine — coordinated with a copper(II) ion. The peptide occurs naturally in human plasma at high concentrations in young adults (~200 ng/mL), declining substantially by age 60 (~80 ng/mL). This natural decline drives much of the research interest in supplementing exogenous GHK-Cu.

Key facts about GHK-Cu:

Chemical class — copper-coordinated tripeptide (3 amino acids)
Molecular weight — approximately 401 Da (340 Da for the peptide + ~62 Da for the copper coordination)
Sequence — Gly-His-Lys (glycyl-L-histidyl-L-lysine)
Form — typically supplied as lyophilized blue-colored powder (color comes from the copper coordination); reconstituted with bacteriostatic water
Cosmetic-grade exists — GHK-Cu is permitted as a cosmetic ingredient in skincare products at controlled concentrations
Research-grade exists — sold under research-use-only labeling for in-vitro and animal research, typically 99%+ purity

The blue color of properly reconstituted GHK-Cu is a quick visual indicator of the copper coordination — uncomplexed GHK has no significant color. If a GHK-Cu solution appears clear or colorless, the copper coordination may be incomplete or the compound may be primarily uncomplexed GHK rather than GHK-Cu.

GHK-Cu Structure and Chemistry

The GHK-Cu structure is small but chemically elegant. Key features:

Copper coordination at the histidine imidazole — the histidine ring nitrogen is the primary copper-binding site
Additional copper coordination via amine groups — the lysine side chain and N-terminal amine participate in the copper binding pocket
Square-planar copper geometry — the copper(II) ion sits in a defined geometric configuration that determines activity
Naturally occurring — same molecular structure as the GHK-Cu found in human plasma, just synthesized for research-grade purity

The copper coordination is what gives GHK-Cu most of its activity — research has documented different activity profiles for GHK alone versus GHK-Cu. The copper ion isn’t an accessory; it’s central to the compound’s mechanism.

How GHK-Cu Works in Research (Mechanism)

Unlike most research peptides that act through a single receptor, GHK-Cu has been documented to modulate multiple biological pathways simultaneously. This is one of the unusual features that drives research interest. Documented mechanisms include:

Gene expression modulation — published research has measured GHK-Cu influence on the expression of over 4,000 genes related to repair, regeneration, antioxidant systems, and cellular aging
Copper-dependent enzyme cofactor activity — copper is required for several antioxidant enzymes (most notably superoxide dismutase), and GHK-Cu participates in copper delivery to these systems
Collagen synthesis upregulation — fibroblast cultures exposed to GHK-Cu produce measurably more Type I collagen than control conditions
Glycosaminoglycan synthesis — hyaluronic acid and related GAGs increase in research models
Fibroblast proliferation and migration — measured in cell culture studies
Anti-inflammatory effects — pro-inflammatory cytokine modulation in research models
DNA repair pathway engagement — research has documented effects on genes involved in cellular DNA repair

The multi-pathway, multi-target nature of GHK-Cu’s mechanism is what makes the compound interesting in research contexts — it doesn’t fit the “one receptor, one effect” model of most synthetic peptides. The published GHK-Cu research literature on PubMed documents these mechanisms across hundreds of studies.

GHK-Cu Research Applications

GHK-Cu research applications span several research areas, all building on the mechanism diversity:

Skin Biology Research

The largest body of GHK-Cu research focuses on skin biology endpoints — collagen synthesis, fibroblast activity, dermal extracellular matrix biology, and broader skin aging research. The research literature spans cell culture studies, animal dermal models, and topical formulation research.

Wound Healing Research

Animal wound healing models — burn, surgical, diabetic ulcer — have documented GHK-Cu effects on re-epithelialization, granulation tissue formation, and overall wound closure timelines. The mechanism involves multiple pathways: angiogenesis, fibroblast migration, anti-inflammatory effects, and collagen production.

Hair Follicle Research

Research on hair follicle stem cells, follicle cycling, and broader hair biology has documented GHK-Cu effects. Some published research links GHK-Cu to hair density and growth phase markers in animal models.

Antioxidant System Research

Copper is a cofactor for several antioxidant enzymes (Cu/Zn superoxide dismutase being the most studied). GHK-Cu’s role in copper delivery makes it relevant to antioxidant system research — published studies document effects on cellular oxidative stress markers.

Aging Biology Research

GHK-Cu’s natural decline with age and its broad gene expression effects have driven aging-biology research. Research models studying senescence markers, DNA repair pathways, and cellular aging endpoints have documented GHK-Cu effects across multiple study designs.

Cosmetic-Grade vs Research-Grade GHK-Cu

GHK-Cu is unusual among research peptides because it exists in two distinct legal categories in the United States:

Category	Cosmetic-Grade	Research-Grade
Form	Finished cosmetic product	Lyophilized research vial
Sold as	Skincare serum, cream	Research peptide
Intended for	Topical cosmetic use	In-vitro and animal research
Regulation	FDA cosmetic regulations	Research-use-only labeling
Concentration	Controlled (typically 0.5-2% in formulation)	Pure compound for research dosing
Purity standards	Cosmetic-grade (variable)	99%+ HPLC-MS verified

The two categories serve different purposes and are not interchangeable. Cosmetic-grade GHK-Cu is designed for topical use within finished products. Research-grade GHK-Cu is a reagent for laboratory studies, sold under research-use-only labeling and never for human consumption.

GHK-Cu Dosing in Research Models

Research dosing of GHK-Cu varies significantly by application area:

Topical research formulations — typically reported in % w/w of finished formulation (0.05-2%); applied to dermal research sites
Cell culture concentrations — typically reported in nM to μM ranges; depends on cell type and endpoint
Animal model injection studies — subcutaneous administration typical; dosing reported in mg/kg body weight
Daily dosing common — GHK-Cu has a relatively short half-life requiring frequent administration in research protocols

Research protocols should always reference published methodology for the specific research model. Topical and injection routes produce different research data and aren’t directly comparable.

GHK-Cu Storage and Stability

GHK-Cu stability requires more attention than most research peptides because of the copper coordination. The copper-peptide complex can be destabilized by:

Strong reducing agents — can strip the copper from the complex
Chelating agents — can sequester the copper away from the peptide
Extreme pH conditions — can disrupt the coordination geometry
Heat and light exposure — standard peptide degradation factors

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our guide on how long do peptides last at room temperature. Protect GHK-Cu from light during storage when possible — opaque containers or refrigerator cardboard boxes work well.

GHK-Cu vs AHK-Cu and Other Copper Peptides

Several related copper peptides exist in research contexts. Brief comparison:

Compound	Sequence	Main Research Focus
GHK-Cu	Gly-His-Lys + Cu	Most studied; broad research applications
AHK-Cu	Ala-His-Lys + Cu	Hair research; complementary to GHK-Cu
GHK (uncomplexed)	Gly-His-Lys (no copper)	Limited research; different activity profile
Custom copper peptides	Various	Emerging research area

GHK-Cu remains the most-cited research compound in this family due to its substantial published literature and well-characterized mechanism. Other copper peptides extend the research into specific applications (AHK-Cu in hair biology, custom variants for receptor-specific research).

How to Identify Quality Research-Grade GHK-Cu

Research-grade GHK-Cu quality criteria differ slightly from other peptides because of the copper coordination:

Blue-colored lyophilized powder — confirms the copper is coordinated with the peptide; a white powder may indicate uncomplexed GHK
99%+ HPLC-MS verified purity — confirms the compound is GHK-Cu, not degradation products
Per-lot Certificate of Analysis — each batch independently tested
Mass spectrometry identity confirmation — confirms molecular weight matches GHK-Cu (~401 Da)
Copper content verification — confirms the copper coordination is present, not just GHK peptide alone
Research-use-only labeling — required for the non-cosmetic, non-pharmaceutical category

At OPS Peptide Science, every GHK-Cu vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming HPLC-MS purity and identity verification before opening the vial.

GHK-Cu Regulatory Status

GHK-Cu occupies a unique dual-category position in US regulation:

Cosmetic-grade GHK-Cu — permitted as a cosmetic ingredient in skincare products at controlled concentrations
Research-grade GHK-Cu — sold under research-use-only labeling for in-vitro and animal research
Not FDA-approved as a drug — no pharmaceutical approval for systemic therapeutic use
Not WADA-prohibited — unlike some peptides, GHK-Cu is not on the WADA Prohibited List as of current updates
Not DEA-scheduled — no controlled substance status

For the complete legal framework around research peptides, see our detailed guide on are peptides illegal. According to NIH dermal research literature, GHK-Cu remains an active area of investigation across multiple research applications.

FAQ

What is GHK-Cu?

GHK-Cu is a tripeptide (glycyl-L-histidyl-L-lysine) bound to a copper ion. It occurs naturally in human plasma at concentrations that decline with age and has been extensively studied in skin biology, wound healing, antioxidant, and gene expression research.

What’s the difference between GHK and GHK-Cu?

GHK is the uncomplexed tripeptide. GHK-Cu is the same peptide bound to a copper ion. Research has documented different activity profiles between the two — the copper coordination is functionally important, and most of the documented skin biology and wound healing effects are attributed to the copper-bound form.

How does GHK-Cu affect collagen?

Research has documented GHK-Cu upregulating Type I collagen synthesis in fibroblast cultures. The mechanism involves both direct effects on fibroblast activity and modulation of genes involved in extracellular matrix protein synthesis (decorin, glycosaminoglycans, etc.).

Can GHK-Cu be used with retinol?

Combination research exists but requires careful design — pH and stability interactions can compromise both compounds in direct mixing. Sequenced application (separate products at different times) is the more common research approach. See our detailed guide on can you use peptides with retinol for the complete picture.

Is GHK-Cu legal to buy in the US?

Yes — cosmetic-grade GHK-Cu is permitted as a skincare ingredient. Research-grade GHK-Cu is sold under research-use-only labeling for in-vitro and animal research. Neither is sold or prescribed for human therapeutic consumption.

How is GHK-Cu stored?

Lyophilized GHK-Cu powder stores at -20°C for 18-24 months. Reconstituted GHK-Cu in bacteriostatic water stores at 2-8°C for 21-28 days. Protect from light during storage. See our complete guide on peptide refrigeration requirements.

Where can I buy research-grade GHK-Cu?

Research-grade GHK-Cu is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include blue-colored lyophilized powder (confirming copper coordination), 99%+ HPLC-MS verified purity, and per-lot Certificates of Analysis. Browse the OPS Peptide Science catalog for verified research-grade GHK-Cu.

GHK-Cu stands out among research peptides for its multi-pathway mechanism, its natural occurrence in human biology, and its broad applicability across skin biology, wound healing, and aging research. For researchers studying collagen synthesis, dermal biology, gene expression, or antioxidant pathways, GHK-Cu remains one of the most-cited copper peptides in the modern research catalog.

For research-grade GHK-Cu backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Product Pillars, Peptide Education

Tirzepatide: Complete Research Guide to GLP-1/GIP Dual Agonist Peptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: Tirzepatide discussed here as a research compound is intended for in-vitro and animal research applications only. FDA-approved tirzepatide products (Mounjaro, Zepbound) require a prescription from a licensed physician and are distinct from research-grade tirzepatide. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

Tirzepatide is a 39-amino-acid synthetic peptide that activates two incretin receptors simultaneously — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual-receptor mechanism distinguishes it from single-receptor compounds like semaglutide and has produced some of the most robust metabolic effects documented in modern peptide research. FDA-approved as Mounjaro for type 2 diabetes and Zepbound for obesity, tirzepatide also exists as a research-grade compound for in-vitro and animal study. This complete guide from the chemistry team at OPS Peptide Science walks through what tirzepatide is, how the dual-agonist mechanism works, and where it sits in the broader research catalog.

For the foundational research-workflow protocols, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is Tirzepatide?

Tirzepatide is a synthetic peptide engineered to activate two distinct incretin receptors: GLP-1R (the same receptor activated by semaglutide) and GIPR (a second incretin receptor not addressed by semaglutide). This dual-receptor approach produces metabolic effects beyond what GLP-1 activation alone delivers.

Key facts about tirzepatide:

Chemical class — 39-amino-acid synthetic dual GLP-1/GIP receptor agonist
Molecular weight — approximately 4814 Da
Half-life — approximately 5 days (supports weekly dosing)
Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
FDA-approved products — Mounjaro (T2D), Zepbound (obesity)
Research-grade form — same molecule, sold under research-use-only labeling for non-human research

Tirzepatide is newer than semaglutide — FDA-approved as Mounjaro in 2022 and Zepbound in 2023 — but research has accumulated rapidly. The compound has become a focal point in metabolic and obesity research because the dual-receptor mechanism produces measurable effects beyond single-receptor GLP-1 agonists across many research endpoints.

Tirzepatide Structure and Chemistry

Tirzepatide’s structure is engineered specifically for the dual-receptor agonism that defines its mechanism. Key features:

Based on native GIP sequence — the peptide backbone derives more from GIP than from GLP-1, despite having activity at both receptors
Strategic amino acid substitutions — engineered for receptor activation at GLP-1R despite the GIP-based backbone
C20 fatty acid chain — attached for albumin binding, extending half-life to ~5 days
Aminoisobutyric acid substitutions — at positions 2 and 13, preventing DPP-4 enzymatic degradation (similar strategy to semaglutide)

The engineering challenge with tirzepatide is achieving meaningful activity at both receptors despite a single molecular backbone. The result is a “biased” agonist with characteristic activity profiles at each receptor — generally stronger GIP activity than native GIP, with GLP-1 activity slightly less potent than native GLP-1 or semaglutide.

How Tirzepatide Works in Research (Dual GIP/GLP-1 Mechanism)

The tirzepatide mechanism cascades through both incretin pathways. The GLP-1 receptor component produces effects familiar from semaglutide research:

Glucose-dependent insulin secretion from pancreatic beta cells
Glucagon suppression in alpha cells
Slowed gastric emptying
Hypothalamic appetite reduction

The GIP receptor component adds:

Additional insulin secretion enhancement — synergistic with GLP-1 in the pancreatic beta cell response
Adipose tissue effects — GIP receptors are expressed in adipose tissue, where the mechanism modulates lipid metabolism
Lipid metabolism modulation — research has documented effects on triglyceride trajectories distinct from GLP-1-only compounds
Centrally mediated appetite effects — GIP receptors in central nervous system tissue contribute to appetite regulation, separate from the GLP-1 hypothalamic pathway

The combination of GLP-1 and GIP activation appears to produce more than the sum of the two mechanisms — research literature documents body composition and metabolic effects that exceed GLP-1-only compounds in head-to-head comparisons. The published tirzepatide research literature on PubMed documents this advantage across multiple study designs.

Tirzepatide Research Applications

Tirzepatide research applications largely mirror semaglutide research, but with documented advantages in several areas:

Metabolic Research

Glucose regulation, insulin sensitivity, and HbA1c trajectory research dominates the tirzepatide literature. The dual receptor mechanism produces stronger metabolic effects than GLP-1-only compounds in head-to-head animal research.

Body Composition Research

Research on adipose tissue, body composition trajectories, and weight management endpoints. The GIP receptor component’s adipose tissue effects appear to produce body composition outcomes that exceed GLP-1-only compounds — a finding documented across multiple research models.

Cardiovascular Research

Cardiovascular biomarker research, lipid profile studies, and broader cardiac endpoint research. Tirzepatide’s lipid metabolism effects extend the cardiovascular research beyond what GLP-1 activation alone delivers.

Liver Research

Emerging research area — tirzepatide’s effects on hepatic glucose production, hepatic lipid content, and broader liver biology in metabolic syndrome research models. The lipid metabolism mechanism produces measurable hepatic endpoints.

Neurological Research

Both GLP-1 and GIP receptors are expressed in brain tissue. Early research has documented neurological effects in animal models, with growing literature on neurodegeneration and cognitive endpoints.

FDA-Approved Tirzepatide vs. Research-Grade Tirzepatide

As with semaglutide, tirzepatide exists in two parallel regulatory categories:

Category	FDA-Approved	Research-Grade
Sold as	Mounjaro, Zepbound	Research peptide vial
Source	Pharmaceutical manufacturer (Eli Lilly)	Research peptide supplier
Prescription required	Yes	No (research-use-only labeling)
Intended for	Human therapeutic use	In-vitro and animal research
Approved indications	T2D (Mounjaro), Obesity (Zepbound)	None (not a drug)
Compound molecule	Tirzepatide	Tirzepatide

The molecule is identical. The regulatory categories are different. FDA-approved tirzepatide is sold as Mounjaro or Zepbound with prescription oversight and regulated pharmaceutical manufacturing. Research-grade tirzepatide is sold for laboratory and animal research under research-use-only labeling — never for human consumption.

For the complete legal framework around research-grade peptides, see our detailed guide on are peptides illegal and the overview on who can prescribe peptides for the prescription pathway.

Tirzepatide Dosing in Research Models

Research dosing of tirzepatide follows patterns similar to semaglutide, with adjustments for the dual-receptor activity:

Weekly subcutaneous administration — matches the 5-day half-life
Dose titration — published research typically titrates over several weeks, especially in body composition studies where higher doses produce stronger effects
4-16 week study duration — body composition and metabolic endpoints develop over multi-week protocols
Animal model dosing — reported in nmol/kg or μg/kg body weight in published research; specific protocols vary by species and endpoint

Research protocols should always reference published methodology for the specific research model. The dual-receptor mechanism means tirzepatide research data can’t be directly extrapolated from GLP-1-only research — the additional GIP activity changes the response curves.

Tirzepatide Storage and Stability

Tirzepatide stability is similar to other large lyophilized research peptides:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our guide on how long do peptides last at room temperature.

Tirzepatide vs Semaglutide: Research Comparison

The question of how tirzepatide compares to semaglutide is one of the most-researched in modern metabolic peptide science. Documented differences in head-to-head research:

Property	Tirzepatide	Semaglutide
Receptor profile	Dual GLP-1 + GIP agonist	GLP-1 agonist only
Amino acids	39	31
Molecular weight	~4814 Da	~4114 Da
Half-life	~5 days	~7 days
Dosing frequency	Weekly	Weekly
Body composition effects in research	Stronger (head-to-head)	Established benchmark
Lipid metabolism research	Additional GIP-mediated effects	GLP-1 mediated only

Tirzepatide’s advantage in body composition research comes primarily from the GIP receptor component — both the additional insulin secretion enhancement and the direct adipose tissue effects. For research focused specifically on body composition endpoints, tirzepatide has become the more-cited compound. For glucose-regulation-focused research, both compounds remain heavily used depending on the specific study design.

How to Identify Quality Research-Grade Tirzepatide

Tirzepatide’s complexity (39 amino acids with multiple modifications and a fatty acid chain) makes purity verification especially important. Quality criteria for research-grade tirzepatide:

99%+ HPLC-MS verified purity — synthesis of large modified peptides produces measurable degradation products; high purity is essential for reproducible research
Per-lot Certificate of Analysis — each batch independently tested with chromatographic profile
Mass spectrometry identity confirmation — confirms molecular weight matches tirzepatide (~4814 Da), distinguishing from related compounds
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every tirzepatide vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming the full HPLC-MS purity report and identity verification before opening the vial.

Tirzepatide Regulatory Status

Tirzepatide regulatory status parallels semaglutide’s:

FDA-approved for human therapeutic use — Mounjaro (T2D, 2022) and Zepbound (obesity, 2023)
Sold as prescription drug through licensed pharmacies
Research-grade form sold under research-use-only labeling — same molecule, different regulatory category, not for human consumption
WADA-prohibited in athletic competition
Not DEA-scheduled — no controlled substance status

The FDA’s Drugs@FDA database lists the approved tirzepatide products. For research use of the molecule, the research-use-only framework applies.

FAQ

What is tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that simultaneously activates two incretin receptors: GLP-1R and GIPR. It is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). It also exists as a research-grade compound sold under research-use-only labeling for in-vitro and animal study.

Is tirzepatide better than semaglutide?

In head-to-head research, tirzepatide produces stronger body composition effects than semaglutide due to its dual GLP-1/GIP agonism. For glucose-regulation endpoints, both compounds are heavily used. “Better” depends on the specific research question — tirzepatide’s advantage is most pronounced in adipose tissue and lipid metabolism research.

Is research-grade tirzepatide the same as Mounjaro?

The molecule is the same — both are tirzepatide. The regulatory categories are different. Mounjaro is the FDA-approved pharmaceutical product sold by prescription. Research-grade tirzepatide is the same molecule sold for laboratory and animal research under research-use-only labeling, not for human consumption.

How long does tirzepatide stay in the body?

Tirzepatide has a half-life of approximately 5 days, supporting weekly dosing in research models. Full clearance from the system takes 4-5 half-lives (about 3-4 weeks) after the last dose.

How does tirzepatide work differently than semaglutide?

Both activate GLP-1 receptors with similar effects (insulin secretion, appetite reduction, slowed gastric emptying). Tirzepatide additionally activates GIP receptors, adding adipose tissue effects, additional insulin secretion enhancement, and lipid metabolism modulation. The dual mechanism produces stronger body composition effects in research.

How is tirzepatide stored?

Lyophilized tirzepatide powder stores at -20°C for 18-24 months. Reconstituted tirzepatide in bacteriostatic water stores at 2-8°C for 21-28 days. See our complete guide on peptide refrigeration requirements.

Where can I buy research-grade tirzepatide?

Research-grade tirzepatide is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and traceable chain-of-custody. Browse the OPS Peptide Science catalog for verified research-grade tirzepatide.

Tirzepatide represents a step forward in research peptide design — the first dual-incretin agonist to achieve broad research adoption and FDA approval. The dual GLP-1/GIP mechanism produces metabolic and body composition effects that exceed single-receptor compounds in research data. For metabolic, obesity, and cardiovascular research, tirzepatide stands alongside semaglutide as one of the most-studied incretin peptides in the modern catalog.

For research-grade tirzepatide backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Product Pillars, Peptide Education, Research Protocols

Semaglutide: Complete Research Guide to GLP-1 Receptor Agonist Peptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: The semaglutide discussed in this article as a research compound is intended for in-vitro and animal research applications only. FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) require a prescription from a licensed physician and are distinct from research-grade semaglutide. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

Semaglutide is a 31-amino-acid GLP-1 receptor agonist peptide that has become one of the most-studied compounds in modern metabolic research. Originally developed for type 2 diabetes management, semaglutide is now FDA-approved across three commercial products — Ozempic, Wegovy, and Rybelsus — and exists as a separate research compound for in-vitro and animal study. This complete guide from the chemistry team at OPS Peptide Science walks through what semaglutide is, how it works mechanistically, where it sits in metabolic research, and how the FDA-approved forms differ from the research-grade compound.

For the foundational research-workflow protocols this guide assumes, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is Semaglutide?

Semaglutide is a synthetic peptide designed to mimic and extend the action of glucagon-like peptide-1 (GLP-1) — a naturally occurring incretin hormone that regulates blood glucose, insulin secretion, and appetite. Native GLP-1 has a very short half-life (1-2 minutes) due to rapid enzymatic degradation. Semaglutide was engineered to resist this degradation, extending the biological half-life to approximately 7 days.

Key facts about semaglutide:

Chemical class — 31-amino-acid GLP-1 analog with chemical modifications for stability
Molecular weight — approximately 4114 Da
Half-life — approximately 7 days (intentionally engineered to be long-acting)
Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
FDA-approved products — Ozempic (T2D), Wegovy (obesity), Rybelsus (oral T2D)
Research-grade form — same compound, sold under research-use-only labeling for non-human research

Semaglutide is unusual among research peptides in that it has fully completed FDA approval for human therapeutic use. The research-grade version sold by OPS Peptide Science is the same molecule, supplied for laboratory and animal research applications under research-use-only labeling rather than as a prescription pharmaceutical.

Semaglutide Structure and Chemistry

Semaglutide’s design reflects two decades of GLP-1 analog research. Key structural features:

Based on native GLP-1 sequence — 94% similarity to human GLP-1, with critical modifications
Amino acid substitution at position 8 — alanine replaced with aminoisobutyric acid (Aib), preventing DPP-4 enzyme degradation
Fatty acid chain attached — a C18 fatty acid linked via a spacer enables albumin binding, extending the half-life from minutes to days
Substitution at position 34 — lysine replaced with arginine, supporting the fatty acid modification

These three modifications — Aib substitution, fatty acid chain, and lysine substitution — are what transform native GLP-1 (clinically impractical due to 2-minute half-life) into semaglutide (suitable for weekly dosing). The chemistry is elegant and well-documented in the published literature.

How Semaglutide Works in Research (Mechanism)

Semaglutide is a GLP-1 receptor agonist — it binds and activates the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor expressed on pancreatic beta cells, brain cells, and several other tissues. The mechanism cascades:

Pancreatic beta cells — GLP-1R activation stimulates glucose-dependent insulin secretion, increasing insulin in response to elevated blood glucose
Alpha cells (glucagon) — GLP-1R activation suppresses glucagon secretion in hyperglycemic conditions
Gastric emptying — semaglutide slows gastric emptying, reducing post-meal blood glucose spikes
Hypothalamic satiety centers — GLP-1R expression in the brain mediates appetite reduction and increased satiety
Cardiovascular tissue effects — documented in cardiac research, with measurable effects on cardiovascular biomarkers

The combination of pancreatic glucose regulation and hypothalamic appetite reduction explains semaglutide’s dual research applications — metabolic regulation and body composition endpoints. The published semaglutide and GLP-1 research literature on PubMed documents these mechanisms across thousands of studies.

Semaglutide Research Applications

Semaglutide research spans several major application areas:

Metabolic Research

The largest body of semaglutide research focuses on metabolic endpoints — insulin sensitivity, glucose tolerance, HbA1c trajectories, and broader metabolic biomarker panels. Animal models studying glucose homeostasis and insulin resistance produce reproducible data with semaglutide protocols.

Body Composition Research

Research on adipose tissue, body composition trajectories, and weight management endpoints in animal models. The hypothalamic appetite mechanism translates to measurable food intake reduction and body composition changes in research subjects over multi-week protocols.

Cardiovascular Research

GLP-1 receptors are expressed in cardiovascular tissues, and research has documented semaglutide effects on cardiovascular biomarkers, inflammatory markers, and lipid profiles in animal research models. This area has generated substantial clinical-trial literature for the FDA-approved forms.

Neurological Research

Emerging research area — GLP-1R expression in brain tissue has driven research on semaglutide effects in neurodegeneration models, cognitive endpoints, and addiction biology. The findings are early-stage but the research literature is growing rapidly.

Inflammatory Research

Anti-inflammatory effects independent of glucose regulation have been documented in research models. Some research links semaglutide to reduced inflammatory markers in metabolic syndrome-related research.

FDA-Approved Semaglutide vs. Research-Grade Semaglutide

This is the most important distinction for understanding semaglutide in the market. Two parallel categories exist:

Category	FDA-Approved	Research-Grade
Sold as	Ozempic, Wegovy, Rybelsus	Research peptide vial
Source	Pharmaceutical manufacturer (Novo Nordisk)	Research peptide supplier
Prescription required	Yes	No (research-use-only labeling)
Intended for	Human therapeutic use	In-vitro and animal research
Approved indications	T2D, obesity, T2D/CVD risk	None (not a drug)
Compound molecule	Semaglutide	Semaglutide

Critical distinction: the molecule is the same, but the regulatory category is different. FDA-approved semaglutide is sold as a pharmaceutical product with full chain-of-custody, prescription oversight, and regulated manufacturing under cGMP. Research-grade semaglutide is sold for laboratory study under research-use-only labeling — never for human consumption. Selling research-grade semaglutide for human use is illegal regardless of the molecule being identical.

For the complete legal framework, see our detailed guide on are peptides illegal and our overview on who can prescribe peptides.

Semaglutide Dosing in Research Models

Research dosing of semaglutide varies by study design but follows a few common patterns:

Weekly subcutaneous administration — matches the 7-day half-life, allowing steady-state plasma levels in research models
Dose titration — published research typically starts at lower doses and titrates upward to study tolerance and effect curves
4-12 week study duration — most metabolic endpoints require several weeks to demonstrate measurable effects
Animal model dosing — typically reported in μg/kg body weight in published research; specific protocols vary by species and endpoint

The long half-life is what makes semaglutide research practical — weekly dosing is convenient for animal protocols and maintains stable plasma concentrations across the research duration. The acute onset versus cumulative timeline question is addressed in our guide on how long does it take for peptides to work.

Semaglutide Storage and Stability

Semaglutide stability profile is similar to other lyophilized research peptides:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our guide on how long do peptides last at room temperature.

Semaglutide vs Tirzepatide vs Liraglutide

The GLP-1 receptor agonist family includes several research peptides. Brief comparison:

Peptide	Receptor Profile	Half-life	FDA-Approved Brand(s)
Semaglutide	GLP-1 receptor only	~7 days	Ozempic, Wegovy, Rybelsus
Tirzepatide	GLP-1 + GIP dual agonist	~5 days	Mounjaro, Zepbound
Liraglutide	GLP-1 receptor only	~13 hours	Saxenda, Victoza
Retatrutide	GLP-1 + GIP + glucagon receptor triple agonist	~6 days	Not yet FDA-approved (clinical trials)

Research designs comparing these compounds explore the GLP-1-only mechanism (semaglutide) versus dual-receptor (tirzepatide) versus triple-receptor (retatrutide) effects on metabolic endpoints. Each compound has different research applications based on its receptor profile.

How to Identify Quality Research-Grade Semaglutide

Because semaglutide is a high-demand research compound, the supplier market includes variable quality. Quality criteria:

99%+ HPLC-MS verified purity — large peptide synthesis (31 amino acids with modifications) is technically demanding; purity verification is essential
Per-lot Certificate of Analysis — each batch independently tested with full chromatographic profile
Mass spectrometry identity confirmation — confirms the modified molecule matches semaglutide (4114 Da), distinguishing from native GLP-1 fragments or degradation products
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial
Research-use-only labeling — required by US regulations for the non-pharmaceutical product

At OPS Peptide Science, every semaglutide vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity, identity, and chain of custody before opening the vial.

Semaglutide Regulatory Status

Semaglutide regulatory status is unique among research peptides because it has parallel pharmaceutical approval:

FDA-approved for human therapeutic use — three commercial products (Ozempic, Wegovy, Rybelsus) cleared for type 2 diabetes and obesity indications
Sold as prescription drug through licensed pharmacies
Research-grade form sold under research-use-only labeling — same molecule, different regulatory category, not for human consumption
WADA-prohibited in athletic competition (peptide hormones category)
Not DEA-scheduled — no controlled substance status

The FDA’s Drugs@FDA database lists the approved semaglutide products and their indications. For research use of the molecule, the research-use-only framework applies.

FAQ

What is semaglutide?

Semaglutide is a 31-amino-acid synthetic peptide that acts as a GLP-1 receptor agonist. It is FDA-approved as Ozempic (type 2 diabetes), Wegovy (obesity), and Rybelsus (oral type 2 diabetes). It also exists as a research-grade compound sold under research-use-only labeling for in-vitro and animal research.

Is research-grade semaglutide the same as Ozempic?

The molecule is the same — both are semaglutide. The regulatory categories are different. Ozempic is the FDA-approved pharmaceutical product sold by prescription. Research-grade semaglutide is the same molecule sold for laboratory and animal research under research-use-only labeling, not for human consumption.

How long does semaglutide stay in the body?

Semaglutide has an unusually long half-life of approximately 7 days, engineered through chemical modifications that resist enzymatic degradation. This supports weekly dosing in research models. Full clearance from the system takes 4-5 half-lives (about 4-5 weeks) after the last dose.

How does semaglutide work?

Semaglutide binds and activates the GLP-1 receptor (GLP-1R) on pancreatic beta cells, hypothalamic appetite centers, and other tissues. This produces glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and reduced appetite. The combined mechanism produces the metabolic effects documented in research.

What’s the difference between semaglutide and tirzepatide?

Semaglutide is a GLP-1 receptor agonist only. Tirzepatide is a dual GLP-1 and GIP receptor agonist — activating both incretin receptors simultaneously. Research compares the single-receptor versus dual-receptor approaches, with tirzepatide showing additional effects beyond what GLP-1 activation alone produces in metabolic research models.

How is semaglutide stored in research?

Lyophilized semaglutide powder stores at -20°C for 18-24 months. Reconstituted semaglutide in bacteriostatic water stores at 2-8°C for 21-28 days. Standard peptide storage protocols apply — see our guide on peptide refrigeration requirements.

Where can I buy research-grade semaglutide?

Research-grade semaglutide is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and traceable chain-of-custody documentation. Browse the OPS Peptide Science catalog for verified research-grade semaglutide.

Semaglutide stands at the intersection of two regulatory worlds — an FDA-approved pharmaceutical (Ozempic, Wegovy, Rybelsus) and a research-grade compound for laboratory study. The molecule is the same; the contexts and labeling differ. For metabolic, body composition, cardiovascular, and increasingly neurological research, semaglutide remains one of the most-cited research peptides in the modern catalog.

For research-grade semaglutide backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Product Pillars, Peptide Education, Research Protocols

TB-500: Complete Research Guide to Thymosin Beta-4 Peptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: TB-500 is a research peptide intended for in-vitro and animal research applications only. It is not FDA-approved as a drug or therapy. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

TB-500 is the synthetic peptide version of thymosin beta-4 — a naturally occurring 43-amino-acid peptide found throughout human and animal tissues. Research on TB-500 spans cardiac repair, dermal wound healing, corneal injury, and broader cell migration biology. The compound has been a focal point of tissue-repair research for decades, with substantial published literature documenting its actin-binding mechanism and downstream effects. This complete guide from the chemistry team at OPS Peptide Science walks through what TB-500 is, how it works in research models, where it sits in the broader research catalog, and how it pairs with BPC-157 in combination protocols.

For the foundational research-workflow protocols this guide assumes, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is TB-500?

TB-500 is the synthetic, research-grade version of thymosin beta-4 (TB-4) — a 43-amino-acid peptide naturally produced in nearly all human and animal tissues. The “500” designation refers to the research nomenclature, not a fragment number — TB-500 is the full-length thymosin beta-4 sequence, synthesized for laboratory use.

Key facts about TB-500:

Chemical class — 43-amino-acid peptide, synthetic version of naturally occurring thymosin beta-4
Molecular weight — approximately 4963 Da
Source — synthesized to match the natural human thymosin beta-4 sequence
Form — typically supplied as lyophilized (freeze-dried) powder; reconstituted with bacteriostatic water for research administration
Half-life — longer than most small peptides due to tissue binding; effective biological half-life is measured in days rather than hours
Stability — stable at -20°C as lyophilized powder for 18-24 months; reconstituted solutions stable for 21-28 days refrigerated

Unlike many research peptides, TB-500’s natural counterpart (thymosin beta-4) is one of the most abundant peptides in mammalian cells, present at high concentrations in platelets, tissues, and circulating plasma. This means TB-500 research has a robust foundation in the natural biology of the compound — researchers know what the molecule does because cells use it for actin regulation and repair as a normal function.

TB-500 Structure and Chemistry

The TB-500 / thymosin beta-4 sequence is one of the most characterized small peptides in cell biology research. Key structural features:

43 amino acids — longer than most synthetic research peptides, which sit in the 5-15 amino acid range
Actin-binding domain — the central functional region that gives the peptide its primary biological activity
N-terminal acetylation — naturally occurring in human thymosin beta-4; synthetic TB-500 typically reproduces this modification for stability
Highly conserved across species — the thymosin beta-4 sequence is nearly identical across mammals, supporting cross-species research translation

The actin-binding domain is what makes TB-500 functionally interesting — it’s not a hormone analog targeting a single receptor, but a cytoskeletal modulator influencing cell shape, migration, and tissue organization at the structural level.

How TB-500 Works in Research (Mechanism)

The TB-500 mechanism is among the better-characterized of research peptides. Documented activities:

G-actin sequestration — TB-500 binds free G-actin monomers, regulating the dynamic balance between G-actin and F-actin (filamentous actin)
Actin polymerization control — by controlling G-actin availability, TB-500 influences when and where actin filaments form, which determines cell shape and movement
Cell migration regulation — fundamental to tissue repair, where cells must migrate to injury sites
Anti-inflammatory effects — independent of actin binding, TB-500 has been documented to modulate inflammatory pathways
Angiogenesis support — research has measured effects on endothelial cell migration and new blood vessel formation
Stem cell activation — published research documents effects on progenitor cell activity in repair contexts

The actin biology mechanism is what gives TB-500 its broad research applications. Almost any tissue repair process involves cell migration, and cell migration requires actin reorganization — which TB-500 directly influences. The thymosin beta-4 tissue repair literature on PubMed documents the mechanism across hundreds of studies.

TB-500 Research Applications

The research literature on TB-500 covers several major application areas:

Cardiac Research

One of the most extensively studied TB-500 applications is in cardiac injury research. Animal models of myocardial infarction have documented measurable effects on cardiac tissue repair, reduced scar tissue formation, and improved heart function endpoints in TB-500-treated subjects. This research extended to clinical trials in some countries (though TB-500 remains non-FDA-approved in the US).

Dermal Wound Healing Research

Skin injury models — burn, surgical wound, diabetic ulcer — show accelerated re-epithelialization, improved granulation tissue quality, and reduced scarring in TB-500-treated research subjects. The compound’s effects on cell migration directly support the wound-healing process at the cellular level.

Corneal Research

Ocular research includes corneal wound healing models, dry eye research, and corneal epithelial regeneration studies. TB-500 has documented effects on corneal repair markers across multiple animal research models.

Musculoskeletal Research

Tendon, ligament, and muscle injury research uses TB-500 to study cell migration during repair. The published research overlaps with BPC-157 research in this area, though the mechanisms are distinct — BPC-157 works through VEGF and angiogenesis, TB-500 works through actin and cell migration.

Hair Follicle Research

A smaller but documented research area on TB-500 effects on hair follicle stem cells and follicle activity. Animal models have measured changes in follicle cycling and stem cell markers.

TB-500 Dosing in Research Models

TB-500 dosing in published research models has distinct features compared to shorter peptides:

Less frequent dosing — TB-500’s effective biological half-life supports less frequent administration than short-half-life peptides; twice-weekly or weekly protocols appear in published research
Larger absolute dose ranges — because the peptide is larger (43 aa vs. 15 aa for BPC-157), research doses tend to be larger in mg amounts
Subcutaneous or intramuscular — both routes documented in published research; SC is more common
Tissue depot effects — TB-500 binds tissues and produces effects beyond what acute plasma levels would predict, complicating simple pharmacokinetic interpretations

Research protocols should reference published methodology for the specific research model. Tissue-binding behavior means TB-500 dosing protocols require careful design — single doses can produce extended effects, while frequent dosing may not produce proportional additive responses.

TB-500 Storage and Stability

TB-500 stability profile aligns with most lyophilized research peptides:

Storage Condition	Form	Stability Window
-80°C (ultra-low freezer)	Lyophilized powder	3-5+ years
-20°C (standard lab freezer)	Lyophilized powder	18-24 months
2-8°C (refrigerated)	Lyophilized powder	6-12 months
Room temperature	Lyophilized powder	2-4 weeks for transit
2-8°C (refrigerated)	Reconstituted in BAC water	21-28 days

For practical storage protocols, see our companion guide on how long do peptides last at room temperature. Larger peptides like TB-500 (vs. smaller compounds like BPC-157) sometimes show slightly different oxidation susceptibility — protocols that work for both compounds generally cover TB-500 safely.

TB-500 + BPC-157 Combination Research (Wolverine Stack)

One of the most-discussed research applications is the combination of TB-500 with BPC-157 — popularly called the Wolverine Stack in research and biohacking discussions. The rationale:

Different mechanisms — TB-500 acts on actin and cell migration; BPC-157 acts on VEGF, angiogenesis, and multiple signaling pathways
Different half-lives — TB-500’s tissue-binding gives extended effects; BPC-157’s shorter half-life allows acute signaling
Potentially complementary — TB-500 supports the cell migration phase of repair; BPC-157 supports the angiogenesis and inflammation modulation phases
Documented in published research — both compounds appear in combination protocols across animal tissue-repair studies

Research design for combination studies requires separate reconstitution, alternating injection sites, and careful documentation of each compound’s contribution to the endpoint. The Wolverine Stack name is informal — published research literature uses BPC-157 + TB-500 terminology — but the combination protocol is real and documented. See our overview on peptides for healing and recovery for the broader context.

How to Identify Quality TB-500

TB-500’s larger size (43 amino acids vs. 15 for BPC-157) makes it more challenging to synthesize cleanly. Quality criteria for research-grade TB-500:

99%+ purity confirmed by HPLC-MS analysis — synthesis of longer peptides produces more degradation products; purity verification is especially important
Per-lot Certificate of Analysis — each batch independently tested with full chromatographic profile
Mass spectrometry identity confirmation — confirms the molecular weight matches TB-500 (4963 Da), distinguishing from shorter degradation products
Chain-of-custody documentation — traceable from manufacturer through fulfillment
Properly lyophilized appearance — clean white cake at the bottom of the vial, no discoloration or moisture damage
Research-use-only labeling — required by US regulations

At OPS Peptide Science, every TB-500 vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming the full HPLC-MS purity report and identity verification before opening the vial.

TB-500 Regulatory Status

TB-500 / thymosin beta-4 occupies a specific position in US regulatory frameworks:

Not FDA-approved — has not completed clinical trials required for human drug approval in the US
WADA-prohibited — listed under category S2 (peptide hormones, growth factors, related substances), banned in and out of athletic competition
Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
Not DEA-scheduled — no controlled substance status
Some clinical research history — has been studied in clinical trials internationally for cardiac and dermal indications, though not FDA-approved

For the complete legal framework around research peptides like TB-500, see our detailed guide on are peptides illegal. According to NIH research literature, TB-500 remains an active pre-clinical research compound across multiple tissue-repair applications.

FAQ

What is TB-500?

TB-500 is the synthetic, research-grade version of thymosin beta-4 — a 43-amino-acid peptide naturally produced in nearly all human and animal tissues. It is one of the most-studied tissue-repair research peptides, with substantial published literature documenting effects on cardiac, dermal, corneal, and musculoskeletal injury models.

Is TB-500 the same as thymosin beta-4?

Yes — TB-500 is the synthetic research-grade version of thymosin beta-4. The two names refer to the same compound, with “TB-500” being the research nomenclature and “thymosin beta-4” being the biological name. Some sources also use “TB4” as a shorthand.

Is TB-500 legal in the US?

TB-500 is legally sold in the US as a research chemical for in-vitro and animal research, under research-use-only labeling. It is not FDA-approved for human use. WADA has prohibited it in athletic competition.

How long does TB-500 stay in the body in research?

TB-500’s plasma half-life is short, but its biological half-life is much longer due to tissue binding. Effective effects in research models can extend for several days after a single dose — longer than the plasma half-life would suggest. This is why TB-500 research protocols often use less frequent dosing (twice-weekly or weekly) than shorter peptides.

What’s the difference between BPC-157 and TB-500?

Both are tissue-repair research peptides, but they act through different mechanisms. BPC-157 (15 amino acids) acts on VEGF, angiogenesis, and multiple signaling pathways. TB-500 (43 amino acids) acts on actin sequestration and cell migration. They are often combined in research protocols (the Wolverine Stack) because the mechanisms complement rather than overlap.

How is TB-500 administered in research?

Most published TB-500 research uses subcutaneous injection. Intramuscular injection also appears in some research protocols. Less frequent dosing schedules (twice-weekly or weekly) are common due to TB-500’s tissue-binding properties and extended biological half-life. See our complete guide on how are peptides administered for context across administration routes.

Where can I buy research-grade TB-500?

Research-grade TB-500 is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and traceable chain-of-custody. Browse the OPS Peptide Science catalog for verified research-grade TB-500.

TB-500 (thymosin beta-4) stands out among research peptides for its mechanistic clarity, its broad tissue-repair research applications, and its strong pairing with BPC-157 in combination protocols. For researchers studying tissue repair, cell migration, cardiac biology, or dermal endpoints, TB-500 is one of the most-cited compounds in the modern research catalog.

For research-grade TB-500 backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026

Peptide Education, Product Pillars, Research Protocols

BPC-157: Complete Research Guide to the Body Protection Compound Peptide

Posted on May 22, 2026May 22, 2026 by admin

22
May

Research Use Only Notice: BPC-157 is a research peptide intended for in-vitro and animal research applications only. It is not FDA-approved as a drug or therapy. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.

BPC-157 — short for Body Protection Compound-157 — is one of the most extensively studied research peptides in modern compound science. A 15-amino-acid synthetic peptide originally identified in gastric juice, BPC-157 has been the focus of hundreds of published animal and in-vitro studies investigating tissue repair, anti-inflammatory effects, and signaling pathway modulation. This complete guide from the chemistry team at OPS Peptide Science walks through what BPC-157 is, what the research literature documents, how researchers handle it in protocols, and where it sits in the broader peptide research catalog.

For the foundational research-workflow protocols this guide assumes, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is BPC-157?

BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence originally identified in human gastric juice. The name “Body Protection Compound” reflects the research history — BPC-157 was first studied in gastrointestinal protection contexts before researchers documented its broader effects across tissue types.

Key facts about BPC-157:

Chemical class — short peptide (15 amino acids), synthetic version of a naturally occurring gastric sequence
Molecular weight — approximately 1419 Da
Sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (single-letter: GEPPPGKPADDAGLV)
Form — typically supplied as lyophilized (freeze-dried) powder; reconstituted with bacteriostatic water for research administration
Half-life — short, approximately 4-6 hours in research models
Stability — stable at -20°C as lyophilized powder for 18-24 months; reconstituted solutions stable for 21-28 days refrigerated

BPC-157 is one of the most-searched research peptides because the published literature is substantial — hundreds of animal studies and in-vitro experiments document effects across multiple research models. The compound is not FDA-approved and is sold legally in the US only as a research chemical under research-use-only labeling.

BPC-157 Structure and Chemistry

The BPC-157 sequence is unusual for a research peptide. Most synthetic peptides are designed analogs of larger hormones (insulin fragments, growth hormone secretagogues). BPC-157 instead originates from the protein BPC (Body Protection Compound) found in gastric juice. The “157” in its name refers to the partial sequence position from the parent BPC protein.

Structurally significant features:

High proline content — five proline residues (positions 3, 4, 5, 8) give the peptide structural rigidity and unusual resistance to enzymatic degradation
Gastric origin — the parent protein evolved to function in the stomach environment, giving BPC-157 unusual stability under acidic and enzymatic conditions
Stable in gastric environment — published research has documented some oral bioavailability for BPC-157 due to this gastric stability, though most research protocols use injection administration

This proline-rich sequence is part of why BPC-157 became such an active research compound — its stability profile is unusually favorable for a small peptide, allowing reliable research dosing protocols.

How BPC-157 Works in Research (Mechanism)

The BPC-157 mechanism is not characterized by a single receptor binding event — research has documented effects across multiple biological pathways, which is unusual for synthetic peptides and contributes to its broad research interest. Documented pathways include:

VEGF (Vascular Endothelial Growth Factor) modulation — BPC-157 has been documented to upregulate VEGF expression, which drives angiogenesis (new blood vessel formation)
Nitric oxide system interactions — research literature shows BPC-157 influences both NO synthesis and the NO system’s vasodilation effects
Growth hormone receptor expression — published studies have documented increased growth hormone receptor expression in tendon and other tissue research models
Inflammatory pathway modulation — measured reductions in pro-inflammatory cytokines (IL-6, TNF-α) in animal injury models
Dopaminergic system effects — some research literature documents effects on dopamine systems, suggesting central nervous system activity
Serotonin system effects — published animal research has measured serotonin modulation in some research models

The multi-pathway nature of the BPC-157 mechanism is what makes the compound interesting in research contexts — it doesn’t fit the typical one-receptor-one-effect model of most synthetic peptides. The BPC-157 research literature on PubMed documents these pathways across hundreds of studies, though the overall mechanistic picture remains incomplete in published literature.

BPC-157 Research Applications

Research literature documents BPC-157 effects across several major application areas:

Tendon and Ligament Research

The most extensively studied BPC-157 application is in tendon and ligament repair research. Multiple animal models — Achilles tendon transection, medial collateral ligament injury, muscle crush — have documented faster repair markers, improved tensile strength recovery, and accelerated cell migration in BPC-157-treated subjects compared to controls.

Gastrointestinal Research

BPC-157’s gastric origin gives it natural research relevance for GI applications. Published research includes ulcer healing models, inflammatory bowel disease models, and gastrointestinal barrier function studies. The compound shows measurable effects on mucosal healing markers in animal models.

Muscle and Soft Tissue Repair

Beyond tendons, BPC-157 research extends into skeletal muscle injury models, soft tissue inflammation, and post-traumatic recovery markers in animal subjects. Published studies have documented effects on muscle satellite cell activity and fiber regeneration markers.

Bone Research

Animal models of bone fracture and bone graft research have documented BPC-157 effects on bone healing markers, callus formation, and bone density endpoints. The mechanism appears to involve the VEGF angiogenesis pathway that supports bone tissue regeneration.

Neural Research

Smaller but growing research body on BPC-157 effects in neural injury models, traumatic brain injury research, and neuroprotection contexts. The dopaminergic and serotonergic system effects suggest broader CNS activity than was originally characterized.

BPC-157 Research Studies and Literature

The BPC-157 research literature spans approximately 30 years, originating primarily from research programs at the University of Zagreb (Croatia) and expanding to research groups worldwide. The published research base includes:

Hundreds of animal studies — predominantly rodent models, with smaller numbers in larger animals
In-vitro cell culture studies — fibroblast, endothelial, and muscle cell research
Pharmacokinetic characterization — half-life, distribution, and clearance data in animal models
Mechanism investigation — receptor binding studies, pathway analysis, gene expression research
Comparative studies — BPC-157 compared to other tissue-repair compounds in similar research models

Notably absent: large-scale human clinical trials. BPC-157 has not completed the FDA approval pipeline. Research remains primarily animal and in-vitro, with the compound sold in the United States only as a research chemical for laboratory study.

BPC-157 Dosing in Research Models

Research dosing of BPC-157 varies significantly across published studies. Common patterns in the literature:

Animal model dosing — typically reported in μg/kg body weight, with daily or twice-daily subcutaneous administration
In-vitro cell culture concentrations — typically reported in nM or μM in published research
Protocol duration — most published studies run 1-4 weeks of consistent dosing to capture tissue-level effects
Administration route — subcutaneous injection is the most common in published animal research, with some studies using intramuscular or oral administration

Research protocols should always reference published methodology for the specific research model. The optimal dosing varies by animal species, research endpoint, and specific injury or condition being studied. For practical research-workflow setup, see our guide on what size syringe for peptides for the standard equipment used in subcutaneous BPC-157 administration.

BPC-157 Storage and Stability

BPC-157 stability profile is among the more favorable for small research peptides, owing to its proline-rich structure:

Storage Condition	Form	Stability Window
-80°C (ultra-low freezer)	Lyophilized powder	3-5+ years
-20°C (standard lab freezer)	Lyophilized powder	18-24 months
2-8°C (refrigerated)	Lyophilized powder	6-12 months
Room temperature	Lyophilized powder	2-4 weeks for transit
2-8°C (refrigerated)	Reconstituted in BAC water	21-28 days

For detailed stability and storage protocols, see our guide on how long do peptides last at room temperature.

BPC-157 + TB-500 Combination Research (Wolverine Stack)

One of the most-discussed BPC-157 research applications is its combination with TB-500 (Thymosin Beta-4) — popularly called the “Wolverine Stack” in research and biohacking discussions. The rationale for combination research:

Different mechanisms — BPC-157 acts on VEGF/angiogenesis pathways; TB-500 acts on actin/cell migration
Potentially additive effects — the two pathways could combine without overlapping, producing additive tissue-repair effects
Documented in published research — both compounds appear in combination protocols across animal research studies

Research design for combination studies requires separate reconstitution, separate injection sites, and careful documentation of each compound’s contribution. See our companion overview on peptides for healing and recovery for the broader context on these compounds.

How to Identify Quality BPC-157

The research peptide market includes vendors of varying quality. Quality BPC-157 research-grade peptide has these characteristics:

99%+ purity confirmed by HPLC-MS analysis — purity below this level can compromise research data through unknown contaminants
Per-lot Certificate of Analysis — each batch independently tested and documented, not just a generic spec sheet
Documented mass spectrometry identity — confirms the compound is actually BPC-157 and not a degradation product or contaminant
Chain-of-custody documentation — traceable from manufacturer to fulfillment
Properly lyophilized appearance — should be a clean white cake at the bottom of the vial, not discolored or melted
Research-use-only labeling — required by US regulations for non-FDA-approved compounds

At OPS Peptide Science, every BPC-157 vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot before opening the vial — a key trust signal that distinguishes documented research-grade compound from unverified market peptides.

BPC-157 Regulatory Status

BPC-157 occupies a specific position in US regulatory frameworks:

Not FDA-approved — has not completed clinical trials required for human drug approval
Removed from 503A compounding list in 2023 — pharmacies can no longer compound BPC-157 for prescription use
Added to WADA Prohibited List in 2023 — banned in WADA-governed athletic competition under category S0
Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
Not DEA-scheduled — no controlled substance status

For the complete legal framework around peptides like BPC-157, see our detailed guide on are peptides illegal. According to NIH research literature, BPC-157 remains an active area of pre-clinical investigation despite the regulatory restrictions on human use.

FAQ

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a sequence originally identified in gastric juice. It is one of the most extensively studied research peptides, with hundreds of animal and in-vitro studies documenting effects on tissue repair, angiogenesis, anti-inflammatory pathways, and gastrointestinal research models.

Is BPC-157 legal in the US?

BPC-157 is legally sold in the US as a research chemical for in-vitro and animal study, under research-use-only labeling. It is not FDA-approved for human use and was removed from the 503A pharmacy compounding list in 2023. WADA has prohibited it in athletic competition since 2023.

How long does BPC-157 take to work in research?

Research timeline varies by endpoint and model. Acute anti-inflammatory effects appear within days in animal research models. Tissue-level repair effects (tendon, ligament, muscle healing) typically require 2-4 weeks of consistent dosing. Specific timelines depend on the injury model and the research endpoint being measured.

Can BPC-157 be taken orally in research?

Research literature documents some oral activity for BPC-157 due to its gastric-protein origin and proline-rich structure, which resists digestive degradation better than most peptides. However, most published research protocols use subcutaneous injection because injection bioavailability is more reliable and reproducible than oral.

What’s the difference between BPC-157 and TB-500?

Both are research peptides studied in tissue-repair contexts, but they act through different mechanisms. BPC-157 acts on VEGF/angiogenesis and multiple signaling pathways. TB-500 (Thymosin Beta-4) acts on actin sequestration and cell migration. Combination research (the “Wolverine Stack”) explores whether the two produce additive effects.

How do I store BPC-157?

Lyophilized BPC-157 powder stores at -20°C for 18-24 months. Reconstituted BPC-157 in bacteriostatic water stores at 2-8°C for 21-28 days. See our complete guide on peptide refrigeration requirements for detailed storage protocols.

Where can I buy research-grade BPC-157?

Research-grade BPC-157 is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, and traceable chain-of-custody documentation. Browse the OPS Peptide Science catalog for verified research-grade BPC-157.

BPC-157 occupies a unique position in modern research peptide science — a small synthetic peptide with a substantial published literature base, an unusually favorable stability profile, and documented effects across multiple research applications. For researchers studying tissue repair, gastrointestinal models, or related endpoints, BPC-157 remains one of the most-referenced compounds in the modern research catalog.

For research-grade BPC-157 backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026